uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyper...
October 19 2017 - 7:05AM
YASTEST
~ Issued Patent in the U.S. Covers
Use of FIX-Padua in Gene Therapy ~
~ Divisional patent applications
filed to further strengthen Padua intellectual property position
~
LEXINGTON, Mass. and AMSTERDAM,
the Netherlands, Oct. 19, 2017 (GLOBE NEWSWIRE) -- uniQure
N.V. (NASDAQ:QURE), a leading gene therapy company advancing
transformative therapies for patients with severe medical needs,
today announced that the Company has acquired a patent family, with
claims issued in the U.S., that broadly covers a hyperactive
variant of Factor IX carrying an R338L mutation (often referred to
as "FIX-Padua") and its use in gene therapy for the treatment of
coagulopathies, including hemophilia B. This patent family was
acquired from the inventor, Professor Paolo Simioni, a
renowned hemophilia expert at the University of Padua, Italy, who
is widely recognized as the first to identify this mutant.
Professor Simioni filed a PCT
application on September 15, 2009, and patent applications are
pending in the U.S., Europe, and Canada. The U.S. Patent and
Trademark Office issued U.S. Patent 9,249,405 on February 2, 2016,
which includes claims directed to Factor IX protein with a leucine
at the R338 position of the protein sequence, nucleic acid
sequences coding for this protein, and therapeutic applications,
including gene therapy. Additional fast track divisional patent
applications have also been filed in the U.S. and in Europe that
would further strengthen uniQure's intellectual property
position.
"I have worked my entire career in
the field of coagulopathies, and in my experience the innovation of
FIX-Padua holds great promise for the treatment of hemophilia B,"
said Professor Simioni. "Combined with the known safety profile of
the AAV5 vector, this gene has the potential to significantly
improve the health of hemophilia B patients. I look forward
to working with uniQure as they advance what I believe will be the
most effective gene therapy for patients suffering from hemophilia
B."
Professor Simioni is serving as
advisor and consultant to uniQure for the development of
therapeutic products using his invention of FIX-Padua. He will
assist in the Company's discussions with regulators, investigators,
and key opinion leaders throughout the clinical development of
AMT-061.
"uniQure is very pleased to have
Professor Simioni, a leading expert in hemophilia and FIX-Padua, as
a collaborator and to have acquired his patents on the invention of
FIX-Padua for gene therapy," said Jonathan Garen, chief business
officer of uniQure. "These patents provide uniQure with an enhanced
proprietary position in hemophilia B gene therapy that we can
further leverage for additional patent protection."
About
uniQure
uniQure is delivering on the promise of gene therapy - single
treatments with potentially curative results. We are leveraging our
modular and validated technology platform to rapidly advance a
pipeline of proprietary and partnered gene therapies to treat
patients with hemophilia, Huntington's disease and cardiovascular
diseases. www.uniQure.com
uniQure
Forward-Looking Statements
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar
expressions. Forward-looking statements are based on management's
beliefs and assumptions and on information available to management
only as of the date of this press release. These forward-looking
statements include, but are not limited to, the development of our
gene therapy product candidates, the success of our collaborations
and the risk of cessation, delay or lack of success of any of our
ongoing or planned clinical studies and/or development of our
product candidates, and the scope of protection provided by our
patent portfolio. Our actual results could differ materially from
those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with our
and our collaborators' clinical development activities,
collaboration arrangements, corporate reorganizations and strategic
shifts, regulatory oversight, product commercialization and
intellectual property claims, as well as the risks, uncertainties
and other factors described under the heading "Risk Factors" in
uniQure's Quarterly Report on Form 10-Q filed on August 8, 2017.
Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and we
assume no obligation to update these forward-looking statements,
even if new information becomes available in the future.
uniQure
Contacts
For
Investors:
Maria E.
Cantor
Direct:
339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M.
Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com
For
Media:
Tom
Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: uniQure N.V. via Globenewswire
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2024 to May 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From May 2023 to May 2024